We have noticed an error in the progression-free survival of patients with extramedullary plasmacytoma in our article published in Haematologica in January 2020 (doi: HAEMATOL/2019/219295).
The following sentence in the abstract:
“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 13.6 months and overall survival of 11.4 months.”
Should be replaced by:
“Extramedullary plasmacytoma at relapse had the worst prognosis with a PFS of 9.1 months and overall survival of 11.4 months.”
Likewise, on page 205, the following sentence:
“However, if diagnosed at relapse, PFS and OS were 13.6 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).”
Should be replaced by:
“However, if diagnosed at relapse, PFS and OS were 9.1 months and 11.4 months for EMP compared to 20.9 months (P=0.249) and 39.8 months (P=0.093) for PO, respectively (Table 2 and Figure 1).”
The error was also present in Table 2.
The corrected Table 2 is shown below.
Table 2.
Comparison of response, survival outcomes of extramedullary plasmacytomas (EMP) or paraosseous (PO) patients either at diagnosis or at relapse.
Supplementary Material
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.